Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus second anti-TNF in rheumatoid arthritis after inadequate response to first anti-TNF
2016-001987-12Phase 4Terminated
- Sponsor
- Società Italiana di Reumatologia
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab, etanercept, infliximab, adalimumab, certolizumab pegol and 1 more in rheumatoid arthritis (RA) (2 arms), sponsored by Società Italiana di Reumatologia. Primary endpoint: Good EULAR response at 24 weeks. Started Jan 2021; status: terminated.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-001987-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001987-12.